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Abstract
 
Natural killer (NK) cells express receptors that recognize major histocompatibility complex
(MHC) class I molecules and regulate cytotoxicity of target cells. In this study, we demonstrate
that Ly49A, a prototypical C-type lectin–like receptor expressed on mouse NK cells, requires
 
species-specific determinants on 
 
b
 
2-microglobulin
 
 
 
(
 
b
 
2m) to recognize its mouse MHC class I
 
ligand, H-2D
 
d
 
. The involvement of 
 
b
 
2m in the interaction between Ly49A and H-2D
 
d
 
 is also
demonstrated by the functional effects of a 
 
b
 
2m-specific antibody. We also define three resi-
dues in 
 
a
 
1/
 
a
 
2 and 
 
a
 
3 domains of H-2D
 
d
 
 that are critical for the recognition of H-2D
 
d
 
 on tar-
get cells by Ly49A. In the crystal structure of the Ly49A/H-2D
 
d
 
 complex, these residues are
involved in hydrogen bonding to Ly49A in one of the two potential Ly49A binding sites on
H-2D
 
d
 
. These data unambiguously indicate that the functional effect of Ly49A as an MHC
class I–specific NK cell receptor is mediated by binding to a concave region formed by three
structural domains of H-2D
 
d
 
, which partially overlaps the CD8 binding site.
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b
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Introduction
 
NK cells are a population of lymphocytes with an ability to
spontaneously kill tumor cells and infected cells (1). Target
recognition by NK cells involves MHC class I molecules on
target cells (2). NK cells express C-type lectin–like or Ig-
like receptors for MHC class I molecules (3, 4). Engage-
ment of these MHC class I receptors by its ligands inhibits
or activates NK cells, depending on a motif found in the cy-
toplasmic region or a positively charged amino acid residue
in the transmembrane segment of the receptors (3, 5, 6).
 
Mouse NK cells express receptors of the Ly49 family,
 
comprised of 
 
.
 
10 members. These molecules are ho-
modimers of type II transmembrane proteins with C-type
lectin–like domains in the extracellular region (7–12).
Ly49A, the prototype member of this family, is an inhibi-
tory receptor specific for the mouse MHC class I molecules
 
H-2D
 
d
 
 and H-2D
 
k
 
 (13). MHC class I is a ternary complex
of a heavy chain, which consists of 
 
a
 
1/
 
a
 
2 and 
 
a
 
3 domains,
 
b
 
2-microglobulin (
 
b
 
2m),
 
1
 
 and a peptide bound to a groove
in the 
 
a
 
1/
 
a
 
2 domain (14). Several lines of evidence sug-
gested the involvement of the 
 
a
 
1/
 
a
 
2 domain in the recog-
nition of H-2D
 
d
 
 by Ly49A. The 34-5-8S antibody, which
recognizes the 
 
a
 
1/
 
a
 
2 domain of H-2D
 
d
 
, but not an anti-
body against the 
 
a
 
3 domain (34-2-12S) inhibits functional
and physical interaction between Ly49A and H-2D
 
d
 
 (13,
15). Ly49A recognizes the natural mutant MHC class I
molecule dm-1, which has the 
 
a
 
1 and NH
 
2
 
-terminal half of
the 
 
a
 
2 domain of H-2D
 
d
 
 with the rest of the molecule de-
rived from H-2L
 
d
 
, which is not a ligand for Ly49A (16).
Ly49A recognizes only the peptide-bound form of H-2D
 
d
 
molecules, but there is no apparent specificity for peptides
as long as they have the anchoring residues required to bind
H-2D
 
d
 
 (17, 18). Despite the homology of Ly49A to C-type
lectins, the ability of Ly49A to bind certain carbohydrates
like fucoidan or dextran sulfate (19), and the presence of
two Asn-linked carbohydrates in H-2D
 
d
 
, binding of Ly49A
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b
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Identification of the Functional Ly49A Binding Site on H-2D
 
d
 
to H-2D
 
d
 
 does not depend on carbohydrates on H-2D
 
d
 
(20). Our previous study using D
 
d
 
/K
 
d
 
 chimeric molecules
has shown that the polymorphic determinant of H-2D
 
d
 
 that
restricts Ly49A reactivity lies in the NH
 
2
 
-terminal halves of
 
a
 
1 and 
 
a
 
2 regions of H-2D
 
d
 
 that form the bottom of the
 
a
 
1/
 
a
 
2 domain (20). Recently, Tormo et al. (21) resolved
the crystal structure of the Ly49A/H-2D
 
d
 
 complex, provid-
ing two possible Ly49A binding sites on H-2D
 
d
 
, and sug-
gested that site 1, which includes the NH
 
2
 
 terminus of 
 
a
 
1
 
a
 
-helix and COOH terminus of 
 
a
 
2 
 
a
 
-helix, is the func-
tional binding site for Ly49A rather than site 2, a concave
region formed by 
 
a
 
1/
 
a
 
2 and 
 
a
 
3 domains, and 
 
b
 
2m. How-
ever, experimental data explaining which represents the
functional Ly49A binding site on H-2D
 
d
 
 that leads to inhi-
bition of NK cell cytotoxicity had been missing.
In this study, we first focused on 
 
b
 
2m, which had not
been thought to be involved in the recognition of H-2D
 
d
 
by Ly49A, and demonstrate the essential role of 
 
b
 
2m in rec-
ognition. This result led us to explore a panel of individually
Ala-substituted mutants of H-2D
 
d
 
, in which mutations were
introduced into 
 
a
 
1/
 
a
 
2 or 
 
a
 
3 domains, to functionally in-
teract with Ly49A. We found specific residues in the 
 
a
 
1/
 
a
 
2
and 
 
a
 
3 domains of H-2D
 
d
 
 that are critically important
for Ly49A interaction, as determined by soluble Ly49A
(sLy49A) binding and inhibition of cytotoxicity by Ly49A
 
1
 
NK cells. Surprisingly, our results indicate that site 2 rather
than site 1 is the functional binding site of Ly49A on H-2D
 
d
 
that results in the inhibition of NK cell cytotoxicity.
 
Materials and Methods
 
Mice. 
 
C57BL/6J mice were obtained from Clea. This study
was approved by the Animal Experiment Review Board of the
Faculty of Pharmaceutical Sciences at The University of Tokyo,
Tokyo, Japan.
 
Cells and Antibodies.
 
C1498 cells, which have C57BL/6 ori-
gin with H-2
 
b
 
 and 
 
b
 
2m
 
b
 
, and Daudi cells were obtained from
American Type Culture Collection. Ly49A-transfected Chinese
hamster ovary (CHO
 
) 
 
cells and H-2D
 
d
 
-, K
 
d
 
-, or L
 
d
 
-transfected
C1498 cells were established as described (13, 19, 20). Ly49A
 
1
 
IL-2–activated NK cells were prepared from C57BL/6 mouse
splenocytes as described (13). S19.8 (anti–mouse 
 
b
 
2m
 
b
 
; reference
22), BBM1 (anti–human 
 
b
 
2m; reference 23), 34-5-8S (anti–
H-2D
 
d
 
 
 
a
 
1/
 
a
 
2; reference 24), 34-2-12S (anti–H-2D
 
d
 
 
 
a
 
3; refer-
ence 24), and A1 (anti-Ly49A; reference 25) were purified from
culture supernatants. Fab and F(ab
 
9
 
)
 
2
 
 fragment of antibodies were
prepared with standard methods. Because both of the anti-
 
b
 
2m
antibodies are mouse IgG2b isotypes, it is difficult to make F(ab
 
9)2
fragments; Fab fragments of these antibodies were instead used in
cell-mediated cytotoxicity assays to avoid antibody-dependent
cellular cytotoxicity (ADCC). Daudi cells were transfected by
electroporation with mouse b2mb or human b2m cDNA (a gift
from Dr. R.K. Ribaudo, Molecular Applications Group, Silver
Spring, MD) that was cloned into pApuro vector (26) together
with wild-type H-2Dd cDNA cloned into pHbAPr-1neo vector,
and stable transfectants were established as described (20).
Cell-mediated Cytotoxicity Assay and Cell–Cell Adhesion Assay.
Cell-mediated cytotoxicity of Ly49A1 NK cells against H-2Dd–
transfected C1498 cells was tested by a 4-h 51Cr-release assay as
described (20). All cytotoxicity assays were done in triplicate.
When indicated, target or Ly49A1 NK cells were preincubated
for 15 min with anti–MHC class I or anti-Ly49A antibodies, re-
spectively. To prevent ADCC, anti-b2m and anti–H-2Dd anti-
bodies were used as Fab and F(ab9)2 fragments, respectively. In-
tact antibodies and F(ab9)2 fragments were used at 10 mg/ml and
Fab fragments were used at 40 mg/ml. Binding of H-2Dd–trans-
fected cells to Ly49A-transfected CHO cells was examined as
described previously (15, 20). When indicated, target cells or
Ly49A1 NK cells were preincubated for 15 min with anti–MHC
class I antibodies or anti-Ly49A antibody, respectively.
Preparation of sLy49A Tetramer. sLy49A was prepared as de-
scribed elsewhere (Matsumoto, N., K. Tajima, M. Mitsuki, and
K. Yamamoto, manuscript submitted for publication). In brief,
the extracellular domain of Ly49A with NH2-terminal biotinyla-
tion sequence tag (27) was expressed in Escherichia coli using an ef-
ficient T7 RNA polymerase-based system (28). The recombinant
protein was in vitro refolded by dilution (29) and purified by cat-
ion exchange and gel filtration column chromatography. The
sLy49A was biotinylated by biotin ligase BirA (Avidity). sLy49A
tetramer was formed by incubating the biotinylated sLy49A with
R-PE–conjugated streptavdin (BD PharMingen) at a molar ratio
of 4:1. 
b2m Replacement Studies.  H-2Dd–transfected C1498 cells
were cultured for 16 h in the presence or absence of 4 mM hu-
man b2m (purified from plasma; Calbiochem) in RPMI 1640
free from FCS at 378C. Then the cells were used for flow cytom-
etry or cell-mediated cytotoxicity assay. After 16 h of culture un-
der FCS-free condition, .99% of the cells were viable.
Site-directed Mutagenesis and Stable Transfection of Cells.  Point
mutations were introduced by primer extension with T4 DNA
polymerase using the Altered Sites® II system (Promega) or by se-
quential PCR steps as described by Cormack (30). To introduce
point mutation by the PCR-based technique, we introduced in-
dividual mutations into the 59 fragment of H-2Dd cDNA, which
encodes a signal sequence and a1/a2 domain, or 39 fragment,
which encodes the rest of H-2Dd, by PCR using the following
terminal primers: 59-CCTGCAGGTCGACTCTAGAG-39 and
59-GTTCTTAAGAGCGTAGCATTCCCGTTC-39 for the 59
fragment and 59-CTCTTAAGAACAGATCCCCCAAAGGC-
39 and 59-GGATCCACACCAGGCAGCTG-39 for the 39 frag-
ment. These primers contain SalI, AflII, or BamHI site (indicated
in italics). The sequence of primers used in the first PCR step will
be provided on request. All the PCR reactions were performed
using KOD-Plus-DNA polymerase (Toyobo). Each of the 59 or
39 fragments was subcloned into the SmaI site of pBluescript® II
SK1 (Stratagene), and the sequence was confirmed by reading
both strands using an LS-2000 sequencer (LI-COR). Then, each
of the mutant 59 fragments and wild-type 39 fragment or wild-
type 59 fragment and each of the mutant 39 fragments was direc-
tionally cloned into pHbApr-1neo vector and the constructs
were used for the transfection of C1498 cells by electroporation
as described (20).
Flow Cytometry. Cells were stained with 10 mg/ml of indi-
cated primary antibodies and then with FITC-goat anti–mouse
IgG F(ab9)2. For sLy49A staining, cells were stained with PE-
labeled sLy49A tetramer and then fixed with 0.5% paraformalde-
hyde in PBS. In both cases, the stained cells were analyzed using a
FACScalibur™ with CELLQuest™ software. Binding of the
sLy49A tetramer to each mutant H-2Dd was calibrated, with the
expression of H-2Dd detected by 34-2-12S or 34-5-8S antibodies
in the following formula: sLy49A tetramer binding index 5
(mean fluorescence intensity [MFI] of sLy49A tetramer stained
cells 2 MFI of streptavidin-PE stained cells)/(MFI of 34-2-12S149 Matsumoto et al.
or 34-5-8S stained cells 2 MFI of control antibody stained cells).
sLy49A tetramer binding of each H-2Dd mutant is expressed as
the relative value of the binding index when wild-type H-2Dd is
adjusted to 100. Because introduction of E227A mutation into
H-2Dd abrogated the 34-2-12S epitope, we evaluated the expres-
sion of E227A mutant by reactivity with the 34-5-8S antibody.
Results
Anti–Mouse b2mb Antibody Inhibits Recognition of H-2Dd
by Ly49A.  To investigate the possible involvement of
b2m in the recognition of H-2Dd by Ly49A, we examined
the effect of the S19.8 antibody, which reacts with the b al-
lele of mouse b2m, on the interaction of Ly49A with
H-2Dd in target cell killing assays. In these experiments,
antibody fragments lacking the Fc region were used to
avoid the potential effect of target lysis by ADCC mediated
by NK cells through their Fc receptors. F(ab9)2, or Fab for
IgG2b isotypes, fragments were used. As reported previ-
ously (13), Ly49A1 LAK cells were unable to kill H-2Dd–
transfected C1498 (H-2b) lymphoma cells efficiently (Fig. 1
A). Importantly, the addition of S19.8 Fab fragments to the
killing assay, as well as the positive control anti–H-2Dd a1/
a2 antibody (34-5-8S) F(ab9)2 fragments or intact anti-
Ly49A antibody (A1), reversed the H-2Dd–mediated inhi-
bition of the target cell killing by Ly49A1 LAK cells (Fig. 1
A). By contrast, negative control anti–H-2Dd a3 antibody
(34-2-12S) F(ab9)2 fragments had no effect. We also inves-
tigated the effect of S19.8 antibody on the physical binding
of H-2Dd–transfected C1498 cells to Ly49A-transfected
CHO cells (Fig. 1 B). Anti–mouse b2m antibody, as well
as anti–H-2Dd a1/a2 or anti-Ly49A antibody, completely
abrogated the binding of H-2Dd–transfected C1498 cells to
Ly49A-transfected CHO cells (Fig. 1 B). These results
clearly demonstrate inhibition of the functional and physi-
cal interaction between H-2Dd and Ly49A by the anti-
b2mb antibody S19.8 and suggest the possible involvement
of b2m in Ly49A binding to H-2Dd.
Failure of Ly49A To Recognize H-2Dd Complexed with Hu-
man b2m. b2m bound to MHC class I molecules on the
cells in culture can be replaced by exogenously added b2m
(31, 32). It is conceivable that some MHC class I molecules
on C1498 cells and their transfectants were associated with
bovine b2m, because those cells were maintained in the
presence of FCS. The observation that anti–mouse b2m
antibody completely abrogated the recognition of H-2Dd
by Ly49A (Fig. 1) suggested that H-2Dd complexed with
b2m from bovine or other species might not be recognized
by Ly49A. To investigate the species-specific involvement
of b2m in Ly49A recognition of H-2Dd, we used human
b2m to which a serological reagent was available. Incuba-
tion of H-2Dd–transfected mouse C1498 cells with human
b2m induced expression of human b2m epitope detected
by BBM1 antibody (Fig. 2 A) and decreased expression of
mouse b2m epitope by 34% in MFI compared with
H-2Dd–transfected C1498 cells cultured in the absence of
human b2m (Fig. 2, A and B). Incubation of H-2Dd–trans-
fected C1498 cells with human b2m also increased expres-
sion of H-2Dd by 12.4%, consistent with the reported abil-
ity of human b2m to stabilize surface expression of mouse
MHC class I molecules (33). These data indicate that a sub-
stantial number of H-2Dd molecules were complexed with
human b2m. These cells were then tested for killing by
Ly49A1 NK cells in the presence or absence of various an-
Figure 1. Anti-b2m antibody inhibits Ly49A interaction with its
MHC class I ligand H-2Dd. (A) Reversal of H-2Dd/Ly49A–mediated in-
hibition of target cell killing by anti-b2m antibody. Killing of H-2Dd–
transfected mouse lymphoma C1498 cells by Ly49A1 NK cells in the
presence of various antibodies was examined by standard 51Cr-release as-
say at an E/T ratio of 20:1. Anti–mouse b2m or anti–H-2Dd antibodies
were used as Fab or F(ab9)2 fragments to prevent ADCC. Means 6 SD of
triplicate studies are shown. (B) Inhibition of H-2Dd–transfected cells
binding to Ly49A-transfected cells by anti-b2m antibody. Binding of
H-2Dd–transfected C1498 cells to Ly49A-transfected CHO cells was ex-
amined in the presence of various antibodies. The antibodies were used at
10 mg/ml. Means 6 SD of triplicate studies are shown.
Figure 2. H-2Dd complexed with human b2m cannot protect target
cell killing by Ly49A1 NK cells. H-2Dd–transfected mouse lymphoma
C1498 cells were cultured in the presence (A and C) or absence of human
b2m (B and D). Then the cells were tested for binding of anti–mouse
b2m antibody S19.8 (shaded area), anti–H-2Dd a3 antibody 34-2-12S
(thin line), anti–human b2m antibody BBM1 (bold line), or control anti-
body (dotted line) by flow cytometry (A and B). The cells were tested for
killing by Ly49A1 NK cells in the presence of various antibodies (C and
D) at an E/T ratio of 20:1. Anti-b2m or anti–H-2Dd antibodies were
used as Fab or F(ab9)2 fragments, respectively.150 Identification of the Functional Ly49A Binding Site on H-2Dd
tibodies (Fig. 2 C). To evaluate the interaction of Ly49A
with H-2Dd complexed with human b2m, H-2Dd com-
plexed with mouse b2m was masked by anti–mouse b2m
antibody. Addition of anti–mouse b2m antibody Fab frag-
ments as well as the anti–H-2Dd a1/a2 antibody F(ab9)2
fragments reversed the inhibition of Ly491 NK cell–medi-
ated killing of H-2Dd–transfected C1498 cells cultured in
the presence of human b2m (Fig. 2 C). Further addition of
anti–human b2m antibody Fab fragments did not show any
effect. These data imply that H-2Dd complexed with hu-
man b2m is unable to inhibit killing by Ly49A1 LAK cells;
however, a firm conclusion could not be obtained due to
the incomplete exchange of human b2m for mouse b2m.
To further address this issue, we transfected b2m defec-
tive human cell line Daudi with human or mouse b2m to-
gether with H-2Dd heavy chain (Fig. 3, A and B). We re-
cently prepared sLy49A tetramer, which specifically binds
H-2Dd (Matsumoto, N., K. Tajima, M. Mitsuki, and K.
Yamamoto, manuscript submitted for publication). sLy49A
tetramer bound Daudi cells transfected with mouse b2m
and H-2Dd (Fig. 3 C) but not those transfected with hu-
man b2m and H-2Dd (Fig. 3 D), despite the equivalent
level of H-2Dd expression on those cells (Fig. 3, A and B).
These results clearly demonstrate the species-specific ability
of mouse b2m to support Ly49A binding to H-2Dd and
suggest the direct involvement of b2m in the recognition
of H-2Dd by Ly49A.
Disruption of Ly49A Recognition of H-2Dd by the Introduc-
tion of Three Individual Mutations in a1/a2 or a3 Domains
of H-2Dd.  Previous observations indicate the importance
of the a1/a2 domain, especially the NH2-terminal halves of
the a1 and a2 regions of H-2Dd that form the bottom of
the a1/a2 domain, in Ly49A recognition of H-2Dd (16,
34). Moreover, our analysis indicates that b2m may be di-
rectly involved in the recognition. These observations
prompted us to prepare a panel of Ala substituted mutants
of H-2Dd and to explore their interaction with Ly49A.
Residues substituted with Ala were chosen from solvent-
exposed residues in a1/a2 or a3 domain based on the
crystal structure of H-2Dd (35, 36). These sites include the
residues involved in hydrogen bonding between H-2Dd
Figure 3. sLy49A tetramer binds H-2Dd complexed with mouse b2m
but not with human b2m. b2m-defective human Daudi cells were stably
transfected with mouse b2m (A and C) or human b2m (B and D) to-
gether with H-2Dd heavy chain. The cells were assayed for binding of
anti–H-2Dd antibody 34-2-12S (A and B, bold line), control antibody (A
and B, thin line), PE-labeled sLy49A tetramer (C and D, bold line), or
streptavidin-PE (C and D, thin line) by flow cytometry. Staining of these
cells with 34-5-8S gave similar results to 34-2-12S (data not shown).
Figure 4. Expression of H-2Dd mutants on transfected
C1498 cells. Individual Ala substitution of each residue
was introduced into the indicated residues of H-2Dd. Each
mutant is described as original amino acid residue in one
letter code followed by residue number and by A, the one
letter code for Ala. C1498 cells that were untransfected or
transfected with wild-type H-2Dd or individual H-2Dd
mutants other than E227A mutant were stained with 34-2-
12S antibody (bold lines) or control antibody (broken
lines). C1498 cells transfected with H-2Dd E227A mutant
were stained with 34-5-8S (bold lines) or control antibody
(broken lines), because E227A mutation disrupted the 34-
2-12S epitope.151 Matsumoto et al.
and Ly49A at the two putative interaction sites in the crys-
tal structure of the Ly49A/H-2Dd complex reported by
Tormo et al. during the course of this study (21). 
C1498 mouse lymphoma cells were stably transfected
with the mutant H-2Dd cDNA constructs. The transfec-
tants with a similar level of H-2Dd expression, as assayed by
staining with 34-2-12S or 34-5-8S antibodies, were se-
lected for further analysis (Fig. 4). Most of the H-2Dd mu-
tants tested here were equally reactive with both 34-2-12S
and 34-5-8S antibodies (data not shown). However, substi-
tution of Glu227 in the a3 domain of H-2Dd with Ala
(E227A) disrupted the epitope recognized by 34-2-12S but
not of 34-5-8S as reported by Connolly et al. (37). The
panel of H-2Dd mutant transfectants was then assayed for
binding of the sLy49A tetramer (Fig. 5). Individual Ala
substitution of the residues Arg6, Asp122 in the a1/a2 do-
main of H-2Dd, or Lys243 in the a3 domain completely
abrogated the ability of H-2Dd to bind sLy49A tetramer,
whereas substitution of Arg111 partially inhibited the bind-
ing. The rest of the mutants had similar capacities to bind
the sLy49A tetramer as wild-type H-2Dd. The same panel
of H-2Dd mutants was also tested for the ability to protect
tumor cells from killing by Ly49A1 LAK cells (Fig. 6). In-
troduction of R6A, D122A, or K243A mutation into
H-2Dd completely abrogated the protective activity of
H-2Dd against killing by Ly49A1 LAK cells. None of the
other mutations tested here significantly impaired the ability
of H-2Dd to protect C1498 cells from killing by Ly49A1
LAK cells (Fig. 6). Neither one of the H-2Dd mutants
tested here nor wild-type H-2Dd protected C1498 cells
from killing by Ly49A2 LAK cells (data not shown). These
results indicate that Arg6, Asp122, and Lys243 are essential
for the physical binding of Ly49A and also for the func-
tional binding of Ly49A that leads to inhibition of NK cell
cytotoxicity. Importantly, these residues are involved in
hydrogen bonding to Ly49A in one out of two binding
sites in the crystal structure of the Ly49A/H-2Dd complex
(Fig. 7; reference 21).
Discussion
Our data clearly indicate the functional Ly49A binding
site on H-2Dd that is associated with inhibition of NK cell
cytotoxicity. The crystal structure of the Ly49A/H-2Dd
complex defined two possible binding sites for Ly49A on a
single H-2Dd molecule (site 1 and site 2 in Fig. 7; reference
21). Site 2 spans the three structural domains that constitute
the MHC class I molecule, a1/a2, a3, and b2m. Several
new lines of evidence indicate that site 2, rather than site 1,
is the functional binding site for Ly49A. (a) 34-5-8S anti-
body, which recognizes the a1/a2 domain, inhibits the in-
teraction between Ly49A and H-2Dd (Figs. 1 and 2; refer-
ence 13). We recently mapped the epitope of 34-5-8S to a
region containing Glu104 and Gly107 of the H-2Dd heavy
chain (Matsumoto, N., W. Yokoyama, S. Kojima, and K.
Yamamoto, manuscript submitted for publication), which
is located in the neighborhood of site 2 (Fig. 7). (b) The
anti-b2mb antibody S19.8 completely inhibited the func-
tional and physical interaction between Ly49A and H-2Dd
(Fig. 1). S19.8 recognizes an epitope containing Ala85 and
His34 of mouse b2m of b allele (38, 39), which is also jux-
taposed to site 2 (Fig. 7). (c) To bind H-2Dd, Ly49A re-
quired a complex of H-2Dd with mouse b2m, but not with
Figure 5. Binding of sLy49A tetramer to H-2Dd mutant transfectants.
Each of the H-2Dd mutant transfectants was stained with sLy49A tetramer
or streptavidin-PE alone. Binding of sLy49A tetramer to each H-2Dd
mutant transfectant is expressed as relative value to wild-type H-2Dd
transfectants as described in Materials and Methods. The mutants in site 1
and site 2 are represented by white and black bars, respectively. The other
mutants and wild-type are represented by gray bars; R6A, D122A, and
K243A mutations, which virtually disrupted sLy49A tetramer binding, are
located in site 2. Definition for site 1 and site 2 followed that of Tormo et
al. (21) and is shown in Fig. 7.
Figure 6. Inhibition of Ly49A1 LAK cell–mediated killing of tumor
cells by H-2Dd mutants. Each H-2Dd mutant transfectant was assayed for
killing by Ly49A1 LAK cells in the absence or presence of anti-Ly49A an-
tibody or control antibody at an E/T ratio of 20:1. Inhibitory activity of
each H-2Dd mutant is expressed as percent inhibition of target cell killing
mediated by Ly49A in the formula: % inhibition of killing 5 (% specific
cytotoxicity in the presence of the anti-Ly49A antibody A1 2 % specific
cytotoxicity in the absence of the antibody)/(% specific cytotoxicity in the
presence of antibody 1003). Killing assay at an E/T ratio of 4:1 gave sim-
ilar results (data not shown). Control antibody did not show any signifi-
cant effect on killing by Ly49A1 LAK cells (data not shown). The mutants
in site 1 and site 2 are represented by white and black bars, respectively.
The other mutants and wild-type are represented by gray bars.152 Identification of the Functional Ly49A Binding Site on H-2Dd
human or bovine b2m (Figs. 1–3). On the other hand,
H-2Dd complexed with rat b2m can bind Ly49A as shown
by Sundback et al. (40). b2m contributes 25% of the binding
surface in site 2 of the Ly49A/H-2Dd complex structure
(21). Importantly, the surface of b2m has the species-spe-
cific residues found in mouse and rat b2m but not in hu-
man or bovine b2m (data not shown). In particular, in the
crystal structure of the Ly49A/H-2Dd complex, site 2 en-
compasses the side chains of Lys3, Gln29, and Lys58 of
mouse b2m. Of these, Lys3 and Gln29 are replaced with
Arg and Gly, respectively, in human and bovine b2m but
are conserved in rat b2m, suggesting significance of Lys3
and Gln29 in species-specific contribution of b2m to the
interaction between Ly49A and H-2Dd. However, we can-
not exclude the possibility that the replacement in other
residues in human or bovine b2m forces H-2Dd heavy
chain to have a different conformation from H-2Dd com-
plexed with mouse or rat b2m. Mutation analysis is in
progress to identify b2m residues that account for the spe-
cies specificity. (d) Ala substituted mutation into any one of
the residues of H-2Dd heavy chain, Arg6 and Asp122 in
a1/a2 and Lys243 in a3, completely abrogated the physi-
cal and the functional interaction between H-2Dd and
Ly49A (Figs. 5 and 6). Introduction of R111A mutation
into a1/a2 of H-2Dd partially inhibited the ability of H-2Dd
to bind Ly49A to such an extent that the effect was not
evident in the functional protection assay (Figs. 5 and
6). Importantly, these four residues are involved in hydro-
gen bonding to Ly49A in site 2 in the crystal structure of
the Ly49A/H-2Dd complex (Fig. 7; reference 21). Interest-
ingly, not all of the Ala substitution of the residues that pu-
tatively disrupt hydrogen bonds between Ly49A and H-2Dd
in site 2 resulted in loss in binding and function: E227A
and E232A mutants of H-2Dd were fully functional in
Figure 7. H-2Dd mutations and antibody
epitopes in the Ly49A/H-2Dd complex. An
MHC class I molecule and Ly49A mole-
cules are depicted as molecular surface and
ribbon diagrams, respectively (the coordi-
nates were provided by Dr. D.H. Margu-
lies, National Institutes of Health, Bethesda,
MD). The bottom view is orthogonal to the
top view. The molecular surface of H-2Dd
heavy chain and b2m are yellow and
pink, respectively. The residues of H-2Dd
that affected Ly49A binding upon Ala sub-
stitution are red or orange and are labeled,
whereas those that did not affect Ly49A
binding upon Ala substitution are dark
green (those in site 1) or light green (oth-
ers). The residues involved in antigenic
epitopes recognized by the anti–mouse
b2m antibody S19.8 and the anti–H-2Dd
a1/a2 antibody 34-5-8S are blue. The gly-
cosylation site Asn86 is magenta. The
graphics image was prepared with Swiss-
PdbViewer (reference 59).153 Matsumoto et al.
binding and protection from killing (Figs. 5 and 6). How-
ever, detailed examination of the crystal structure of the
Ly49A/H-2Dd complex revealed that multiple hydrogen
bonds are provided by each side chain of the residues of
which Ala substitution completely (R6, D122, K243) or
partially (R111) abolished the interaction between Ly49A
and H-2Dd. By contrast, each side chain of the residues
E227 and E232 forms only single hydrogen bond (data not
shown). These differences could account for the observed
absence in binding and functional effects of the E227A and
E232A mutants. (e) Another possible Ly49A binding site
on H-2Dd (site 1) was also revealed by the crystal structure
of the Ly49A/H-2Dd complex (21). None of the Ala sub-
stitutions that were expected to disrupt hydrogen bonds
between Ly49A and site 1 in the crystal structure showed
any effect on sLy49A tetramer binding, or on the func-
tional interaction of H-2Dd with Ly49A (Figs. 5–7). How-
ever, our data do not exclude the possibility that Ly49A in-
teracts with H-2Dd through site 1 so weakly that the
interaction was not detectable by sLy49A tetramer staining.
The weak interaction through site 1 might be associated
with cis interaction between Ly49A and H-2Dd on NK
cells that leads to modulation of the Ly49A receptor as ob-
served by Kåse et al. (43).
Collectively, our current results combined with the crys-
tal structure of the Ly49A/H-2Dd complex (21) unambigu-
ously indicate that the functional binding site of Ly49A lies
in a concave region formed by the bottom of the a1/a2
and a3 domains, and b2m. These results also explain the
previous observation that a single chain H-2Dd molecule,
in which b2m is covalently linked to H-2Dd heavy chain
through a peptide spacer, fails to interact with Ly49A (41).
The peptide spacer is expected to cross in the middle of site
2, thereby interfering with the binding of Ly49A to site 2.
Also, the current data provide a basis for the observation
that the Ly49A binding site on MHC class I is distinct from
the binding site for T cell receptor, which binds the top of
the a1/a2 domain (42). Similarly, the identification of the
binding site for Ly49A provides an understanding of other
observations.
Functional binding of Ly49A to site 2 of H-2Dd well ex-
plains the observation that binding of Ly49A to H-2Dd re-
quires the presence of peptide in the groove of H-2Dd a1/
a2 domain (17, 18). In the crystal structure of the Ly49A/
H-2Dd complex, the side chains of Thr238 and Arg239 of
Ly49A-1, which has a smaller contact area with H-2Dd
than the other Ly49A subunit Ly49A-2 (Fig. 7), are hydro-
gen bonded to main chain carbonyl oxygens of Tyr85 and
Asn86, respectively, both of which are located in the
COOH-terminal end of a1 a-helix (21). The side chain of
Ser192 of Ly49A-1 is hydrogen bonded to the amide
groups of Met138 and Ala139, both of which are in the
NH2-terminal end of a2 a-helix. Binding of a peptide to
the peptide-binding groove of H-2Dd would bring two
a-helices of H-2Dd to a position where Tyr85, Asn86,
Met138, and Ala139 are available for hydrogen bonding to
the residues in Ly49A-1. The notion that mutations in the
peptide-binding groove of H-2Dd deteriorate the interac-
tion between H-2Dd and Ly49A is remarkable in this con-
text (Matsumoto, N., W. Yokoyama, S. Kojima, and K.
Yamamoto, manuscript submitted for publication; refer-
ences 45, 46). It is also noteworthy that the binding of
Ly49C and Ly49I to H-2Kb and Kd, respectively, is re-
stricted by the peptide bound to MHC class I (44, 47). In-
terestingly, position 7, which is proximal to the end of the
groove, of H-2Kb–bound peptide is critically involved in
the peptide specificity of Ly49C binding to H-2Kb (47).
Provided that Ly49C binds to a similar site on H-2Kb as
Ly49A functionally binds H-2Dd (site 2), the peptide
bound to H-2Kb might affect the conformation of the end
regions of the a-helices and thereby influence the binding
of Ly49C.
The functional Ly49A binding site on H-2Dd is located
beneath the a1/a2 domain (Fig. 7), and it partially overlaps
the CD8 binding site (48, 49). CD8 has a stalk region of
30–50 residues, which is highly O-glycosylated (50), and its
extended structure enables the unique Ig-like domain to
reach MHC class I on the opposing target cell (49). Simi-
larly, Ly49A has a stalk region of 68 residues, which con-
nects the C-type lectin–like domain to the transmembrane
domain and has three potential N-glycosylation sites (7, 8).
N-glycosylation on these sites might keep the stalk region
of polypeptide in an extended conformation to enable the
C-type lectin–like domain of Ly49A to reach the recogni-
tion surface beneath the a1/a2 domain of H-2Dd. It is of
note that two of the three N-glycosylation sites were
highly conserved among other Ly49 members (data not
shown).
H-2Dd has two N-glycosylation sites at Asn86 and
Asn176. Results from investigations on the role of carbo-
hydrate moieties in recognition of H-2Dd by Ly49A were
controversial (20, 51, 52). However, it was established that
Ly49A does not require carbohydrates on H-2Dd to inter-
act with H-2Dd (20, 42). Because site 2 is located in the
neighborhood of the N-glycosylation site at Asn86, the
carbohydrate attached to this site might influence the Ly49A
binding. We modeled H-2Dd with a high mannose-type
glycochain on Asn86 by transplanting that from human
CD2, of which dynamic structure including the carbo-
hydrate moiety was determined by nuclear magnetic
resonance (53) (Matsumoto, N., H. Iijima, and K. Yama-
moto, unpublished data). The carbohydrate in any con-
formation found in CD2 is well accommodated in the in-
terface of Ly49A at site 2. Moreover, the model raises the
possibility that the carbohydrate might interact with the
surface of Ly49A that corresponds to the carbohydrate-rec-
ognition surface found in typical carbohydrate-binding
C-type lectins (54). This could account for the finding that
optimal binding of H-2Dd–expressing cells to immobilized
Ly49A is compromised by a sulfation inhibitor (51). The
modeling of the H-2Dd with carbohydrate moieties on
Asn86 also provides an insight into the stoichiometry of
Ly49A binding to H-2Dd. From the model provided by
the crystal structure of the Ly49A/H-2Dd complex, one
Ly49A dimer could associate with two H-2Dd molecules.
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occupied the space where the H-2Dd molecule that inter-
acts through site 1 is supposed to fill. Therefore, the stoi-
chiometry of binding of the Ly49A dimer to the N-glyco-
sylated H-2Dd is postulated to be one to one; when a single
Ly49A dimer on NK cells binds H-2Dd on target cells via
site 2, the same Ly49A molecule would not be able to in-
teract with MHC class I on NK cells via site 1.
Ly49A distinguishes polymorphic MHC class I mole-
cules (Matsumoto, N., K. Tajima, M. Mitsuki, and K.
Yamamoto, manuscript submitted for publication; refer-
ence 44). However, the critical residues identified in this
study are conserved among mouse MHC class I molecules,
including H-2Dd and Dk, which are ligands for Ly49A, and
H-2Db, Kb, and Kd, which are not ligands for Ly49A (data
not shown). Some of the polymorphic residues exposed on
the surface of non-Ly49A ligand MHC class I that corre-
spond to site 2 (data not shown) might determine the reac-
tivity with Ly49A. In this context, we previously reported
that NH2-terminal halves of a1 and a2 regions of H-2Dd
are critically important for the recognition of H-2Dd by
Ly49A by analyzing H-2Dd/Kd chimeric molecules (20).
Sundback et al. (40) also reported the inability of the
H-2Db a2 domain to support recognition of H-2Dd by
Ly49A by exon shuffling between H-2Dd and Db. Muta-
tional studies on H-2Dd revealed that polymorphic residues
inside and outside of the peptide-binding groove affect the
recognition of H-2Dd by Ly49A (45, 46) (Matsumoto, N.,
W. Yokoyama, S. Kojima, and K. Yamamoto, manuscript
submitted for publication). Of particular importance, we
recently found that the substitution of polymorphic Asn30
of H-2Dd with Asp, which is found in non-Ly49A ligands
Kb and Kd, partially abolished the functional as well as
physical recognition of H-2Dd by Ly49A (Matsumoto, N.,
W. Yokoyama, S. Kojima, and K. Yamamoto, manuscript
submitted for publication). The effect of the mutations in
these sites may be conformational, since these residues
identified by mutational studies are not found in the inter-
face between Ly49A and H-2Dd that was functionally
identified in this study (site 2). It should also be noted that a
comparison of the crystal structure of MHC class I mole-
cules revealed variation of the relative orientation of a3
domain or b2m to a1/a2 domain among mouse and hu-
man MHC class I molecules (36). Configuration of these
domains might be critical for the interaction with Ly49A
because Ly49A interacts with the surface of H-2Dd that
spans the a1/a2 and a3 domains, and b2m in site 2 (Fig.
7). Therefore, the structural basis for MHC class I allele
specificity of Ly49A remains to be examined in detail by
site-directed mutagenesis.
The structure of the human Ig-like NK cell receptor
KIR2DL2 in complex with its MHC class I ligand, HLA-
Cw3, has been determined (55). Our analysis clearly dem-
onstrated that Ly49A recognizes the surface of MHC class I
that is distinct from the surface recognized by KIR2DL2.
The interaction of KIR2DL2 with MHC class I is abro-
gated by individual amino acid substitutions of the residues
in KIR2DL2 that disrupt hydrogen bonds between
KIR2DLD and MHC class I (55). Similarly, the presence
of hydrogen bonds critical for Ly49A/H-2Dd association
was shown in our assays (Figs. 5 and 6). Thus, despite the
structural difference and the difference in the binding sites
on MHC class I, binding of the functionally similar recep-
tors Ly49A and KIR2DL2 to MHC class I is critically me-
diated by hydrogen bonds and is very sensitive to individ-
ual disruption of hydrogen bonds.
The identification of the functional Ly49A binding site
on H-2Dd provides a molecular basis for understanding the
recognition of the MHC class I or related molecules not
only by other members of the Ly49 family but also by
other C-type lectin–like NK cell receptors, including
HLA-E or Qa-1 recognition by CD94/NKG2A (56) and
MIC-A, B, and RAE recognition by human and mouse
NKG2D, respectively (57, 58). While our studies predict
that other C-type lectins, such as CD94/NKG2A, may in-
teract with MHC class I–related molecules in the same
way, several findings suggest that there may be differences.
CD94/NKG2A is a heterodimer of two related chains with
unique C-type lectin–like domains, whereas Ly49A is a
homodimer. CD94/NKG2A recognizes the nonclassical
MHC class I molecule HLA-E (Qa-1 in mouse), whereas
Ly49A recognizes the classical MHC class I molecules like
H-2Dd and Dk. Recognition of the MHC class I ligand by
CD94/NKG2A is dependent on the sequence of the MHC
class I–bound peptide (59, 60), whereas Ly49A has no ap-
parent specificity for MHC class I–bound peptide (17, 18).
CD94 and NKG2A have relatively short stalk regions, 28
residues in human CD94 and 24 residues in human
NKG2A, compared with Ly49A, which has a stalk region
of 68 residues. One might argue that the short stalk region
is not compatible with the idea that CD94/NKG2A inter-
acts with the similar site on HLA-E as Ly49A functionally
interacts with H-2Dd. However, the stalk regions with 24–
28 residues are able to stretch for at least 8 nm in an ex-
tended conformation and would be capable of placing
C-type lectin–like domains for CD94/NKG2A to bind the
similar site on HLA-E. Biochemical as well as structural
studies on the interaction between other members of the
C-type lectin–like NK cell receptors and their ligands are
needed to show whether the similar sites on MHC class I
or its related molecules are used as receptor binding inter-
face.
Structurally based studies such as this work together
with the recently resolved crystal structures of the
Ly49A/H-2Dd and the KIR2DLD/HLA-Cw3 com-
plexes (21, 55) have unveiled the mode of recognition
of MHC class I molecules by MHC class I–specific NK
cell receptors of the two structurally different families.
These studies are also important with respect to NK cell
biology in general. The missing-self hypothesis predicts
that NK cells monitor the expression of MHC class I
molecules and kill the cells with aberrant expression of
MHC class I associated with such events as tumorigene-
sis or infection (2). The structural studies suggest how
NK cell receptors can sense the aberrant expression of
MHC class I molecules, in addition to global loss of ex-
pression.155 Matsumoto et al.
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